Celularity Regains Nasdaq Compliance on Bid Price and Market Value; Filing Deficiency Remains
CELU has more than doubled off its 52-week low of $0.56.
Summary
Celularity announced Nasdaq has closed two listing compliance matters — minimum bid price and minimum market value — while the delayed periodic filing deficiency remains outstanding.
Key Events · Legal and Risk Events · CELU
-
Nasdaq Closes Two Listing Compliance Matters
On September 11, 2026, Nasdaq confirmed Celularity regained compliance with the minimum bid price rule (5550(a)(2)) and minimum market value of listed securities rule (5550(b)(2)); both matters are now closed.
-
Periodic Filing Deficiency Remains Open
The previously disclosed deficiency under Nasdaq Rule 5250(c)(1) for delayed filing of periodic reports with the SEC remains outstanding; Celularity continues working to complete its delayed filings.
-
Delisting Risk Partially Resolved
This resolves two of three Nasdaq listing deficiencies disclosed in the July 29, 2026 8-K, but the company is not yet fully compliant and still faces delisting risk from the filing deficiency.
Analysis · CELU · Life Sciences
Two of the three Nasdaq listing deficiencies that threatened Celularity's continued listing have now been resolved. The minimum bid price and minimum market value of listed securities requirements are satisfied and closed by Nasdaq. However, the company still has an outstanding deficiency for delayed periodic filings under Rule 5250(c)(1), meaning the delisting risk is not fully eliminated. This is a meaningful positive step for a company that has faced multiple delisting notices and leadership turmoil, but the remaining filing deficiency keeps the situation unresolved.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.